Merrimack investigating whether MM-111 can safely be added to standard therapies used to treat both conventional HER2 positive breast cancers and other HER2 positive solid tumors.
MM-111 first-in-human phase 1/ 2 and pharmacologic study in patients with advanced refractory HER2-Positive (HER2+) cancers. MM-302 pre-clinical safety and activity study of anthracycline delivery to HER2-Positive (HER2+) tumors